Overview

A Study of Topical XG004 in Participants With Osteoarthritis of the Knee

Status:
Recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This is phase 1 placebo controlled study to evaluate the safety, tolerability and pharmacokinetics of XG004 applied topically in participants with osteoarthritis of the knee
Phase:
Phase 1
Details
Lead Sponsor:
Xgene Pharmaceutical Pty Ltd
Collaborator:
Novotech (Australia) Pty Limited